Management of Type 2 Diabetes in Stage C Heart Failure with Reduced Ejection Fraction
Type 2 diabetes is an increasingly common comorbidity of stage C heart failure with reduced ejection fraction (HFrEF). The two diseases are risk factors for each other and can bidirectionally independently worsen outcomes. The regulatory requirement of cardiovascular outcomes trials for antidiabetic...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Radcliffe Medical Media
2022-03-01
|
| Series: | Cardiac Failure Review |
| Online Access: | https://www.cfrjournal.com/articleindex/cfr.2021.31 |
| _version_ | 1797199984518496256 |
|---|---|
| author | Anjali Agarwalla Jadry Gruen Carli Peters Lauren Sinnenberg Anjali T Owens Nosheen Reza |
| author_facet | Anjali Agarwalla Jadry Gruen Carli Peters Lauren Sinnenberg Anjali T Owens Nosheen Reza |
| author_sort | Anjali Agarwalla |
| collection | DOAJ |
| description | Type 2 diabetes is an increasingly common comorbidity of stage C heart failure with reduced ejection fraction (HFrEF). The two diseases are risk factors for each other and can bidirectionally independently worsen outcomes. The regulatory requirement of cardiovascular outcomes trials for antidiabetic agents has led to an emergence of novel therapies with robust benefits in heart failure, and clinicians must now ensure they are familiar with the management of patients with concurrent diabetes and stage C HFrEF. This review summarises the current evidence for the management of type 2 diabetes in stage C HFrEF, recapitulating data from landmark heart failure trials regarding the use of guideline-directed medical therapy for heart failure in patients with diabetes. It also provides a preview of upcoming clinical trials in these populations. |
| first_indexed | 2024-03-07T17:39:57Z |
| format | Article |
| id | doaj.art-64ee33af64ef462bbc9fd739ad5bf392 |
| institution | Directory Open Access Journal |
| issn | 2057-7540 2057-7559 |
| language | English |
| last_indexed | 2024-04-24T07:24:26Z |
| publishDate | 2022-03-01 |
| publisher | Radcliffe Medical Media |
| record_format | Article |
| series | Cardiac Failure Review |
| spelling | doaj.art-64ee33af64ef462bbc9fd739ad5bf3922024-04-20T16:02:47ZengRadcliffe Medical MediaCardiac Failure Review2057-75402057-75592022-03-01810.15420/cfr.2021.31Management of Type 2 Diabetes in Stage C Heart Failure with Reduced Ejection FractionAnjali Agarwalla0Jadry Gruen1Carli Peters2Lauren Sinnenberg3Anjali T Owens4Nosheen Reza5Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USDivision of Cardiovascular Medicine, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, PA, USDivision of Cardiovascular Medicine, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, PA, USDivision of Cardiovascular Medicine, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, PA, USDivision of Cardiovascular Medicine, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, PA, USDivision of Cardiovascular Medicine, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, PA, USType 2 diabetes is an increasingly common comorbidity of stage C heart failure with reduced ejection fraction (HFrEF). The two diseases are risk factors for each other and can bidirectionally independently worsen outcomes. The regulatory requirement of cardiovascular outcomes trials for antidiabetic agents has led to an emergence of novel therapies with robust benefits in heart failure, and clinicians must now ensure they are familiar with the management of patients with concurrent diabetes and stage C HFrEF. This review summarises the current evidence for the management of type 2 diabetes in stage C HFrEF, recapitulating data from landmark heart failure trials regarding the use of guideline-directed medical therapy for heart failure in patients with diabetes. It also provides a preview of upcoming clinical trials in these populations.https://www.cfrjournal.com/articleindex/cfr.2021.31 |
| spellingShingle | Anjali Agarwalla Jadry Gruen Carli Peters Lauren Sinnenberg Anjali T Owens Nosheen Reza Management of Type 2 Diabetes in Stage C Heart Failure with Reduced Ejection Fraction Cardiac Failure Review |
| title | Management of Type 2 Diabetes in Stage C Heart Failure with Reduced Ejection Fraction |
| title_full | Management of Type 2 Diabetes in Stage C Heart Failure with Reduced Ejection Fraction |
| title_fullStr | Management of Type 2 Diabetes in Stage C Heart Failure with Reduced Ejection Fraction |
| title_full_unstemmed | Management of Type 2 Diabetes in Stage C Heart Failure with Reduced Ejection Fraction |
| title_short | Management of Type 2 Diabetes in Stage C Heart Failure with Reduced Ejection Fraction |
| title_sort | management of type 2 diabetes in stage c heart failure with reduced ejection fraction |
| url | https://www.cfrjournal.com/articleindex/cfr.2021.31 |
| work_keys_str_mv | AT anjaliagarwalla managementoftype2diabetesinstagecheartfailurewithreducedejectionfraction AT jadrygruen managementoftype2diabetesinstagecheartfailurewithreducedejectionfraction AT carlipeters managementoftype2diabetesinstagecheartfailurewithreducedejectionfraction AT laurensinnenberg managementoftype2diabetesinstagecheartfailurewithreducedejectionfraction AT anjalitowens managementoftype2diabetesinstagecheartfailurewithreducedejectionfraction AT nosheenreza managementoftype2diabetesinstagecheartfailurewithreducedejectionfraction |